Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.72 |
| ▸ | MTOR | P42345 | 5/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324811 | 1.00 | PIK3CA (0.72) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL14735399 | 0.85 | PIK3CA (0.70) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL4337235 | 0.85 | PIK3CA (0.63) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL1428533 | 0.85 | PIK3CA (0.63) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL29516892 | 0.85 | PIK3CA (0.70) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL6964349 | 0.85 | PIK3CA (0.70) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL29516830 | 0.85 | PIK3CA (0.70) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL4314988 | 0.84 | PIK3CA (0.73) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL4314992 | 0.84 | PIK3CA (0.73) | PIK3CAMTORPIK3CGMEN1KMT2A | |
| SCHEMBL4315259 | 0.83 | PIK3CA (1.00) | PIK3CAMTORPIK3CGTYRCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | claimed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | claimed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | PIK3CA 4/4885MTOR 1/4885PIK3CG 8/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | PIK3CA 942/4885MTOR 103/4885PIK3CG 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.